Identification of potential biomarkers of long non-coding RNAs in neuropathic pain using bioinformatic analysis

A protocol for systematic review and meta-analysis

Yongzhi Fan, MB, Na Li, MB, Xianbao Yao, MB

Abstract

Background: Long non-coding RNAs (LncRNAs) play important roles in the regulation of neuropathic pain (NP) development. LncRNAs dysregulations are related to the development of NP. However, a comprehensive meta-analysis has never been conducted to assess the relationship between LncRNAs and NP. To combine the results of dysregulated LncRNAs in individual NP studies and to identify potential LncRNAs biomarkers.

Methods: LncRNAs profiling studies of NP were extracted from Pubmed, Web of science, Embase, Google Scholar, and Chinese National Knowledge Infrastructure, and the Chinese Biomedical Literature Database if they met the inclusion criteria. The meta-analysis was conducted using a random effects model to identify the effect of each multiple-reported LncRNAs. We also performed subgroup analysis according to LncRNAs detecting methods and sample type. Sensitivity analysis was performed on the sample size. Bioinformatic analysis was performed to identify the potential biomeric functions. All results were represented as log10 odds ratios.

Results: This review will be disseminated in print by peer-review.

Conclusion: The identified LncRNAs may be closely linked with NP and may act as potentially useful biomarkers.

Ethics and dissemination: The private information from individuals will not publish. This systematic review also will not involve endangering participant rights. Ethical approval is not available. The results may be published in a peer-reviewed journal or disseminated in relevant conferences

OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/ZRX7C.

Abbreviation: LncRNA = long non-coding RNA.

Keywords: long non-coding RNA, meta-analysis, neuropathic pain, protocol

1. Introduction

Neuropathic pain (NP) is 1 of the most common chronic pain in humans, and is characterized by increased responsiveness of nociceptive neurons in the peripheral and central nervous system.[1–3] Peripheral and central sensitization represent changes in the functional state of nociceptive neurons and are caused by changes in a large number of functional proteins and signal pathways in neurons and glial cells.[4] NP is a refractory chronic disease that seriously endangers the life quality of patients and brings heavy burden to society and families.[5,6] The whole world spends hundreds of millions of dollars on the treatment of chronic pain every year. However, at present, conventional analgesic drugs are difficult to achieve the ideal analgesic effect.[7–9] Therefore, there is an urgent need to develop new targets for the treatment of NP.

Long non-coding RNAs (LncRNAs) are a new non-coding protein RNA with a transcript of more than 200 bp.[10] Although LncRNAs were initially considered as a transcriptional by-product, recent advances in technology provided a new understanding of their important role in gene regulation and disease pathogenesis.[11,12] Recent data display that LncRNAs can participate in gene expression by regulating transcription, post-transcriptional processing, chromatin remodeling and the
pathogenesis of NP.[16,17] LncRNAs are inflammatory mediators, which play an important role in the activation, leukocyte infiltration and the production of inflammatory mediators.[16–18]

Consequently, meta-analysis is essential to determine the valuable LncRNAs biomarkers and potential therapeutic targets for NP.

So far, no reliable evaluation system has been observed for the relationship between LncRNAs expression and NP. However, there is no systematic comment on the evidence, and the relationship between the expression of LncRNAs and NP is still not fully understood. The objective of this study was to summarize and manage all differentially expressed LncRNAs presented in current NP studies and then conduct a meta-analysis to identify the potential biomarkers of consistently dysregulated LncRNAs which had been shown in reproducible NP studies.

2. Methods

2.1. Study registration

The protocol of the systematic review has been registered on Open Science Framework, and the registration number is DOI 10.17605/OSF.IO/ZRX7C. This meta-analysis protocol is based on the Preferred Reporting Items for Systematic Reviews and meta-analysis (PRISMA) Protocols statement guidelines.[19]

2.2. Data sources and search strategy

The following electronic bibliographic databases are searched to identify relevant studies: Pubmed, Web of science, Embase, Google Scholar, and Chinese National Knowledge Infrastructure, and the Chinese Biomedical Literature, up to December 2020. The combination of Medical Subject Headings words and free words is used in the search. References of the literature are also included. According to different characteristics of the database, the retrieval strategy of title, abstract or keyword is adjusted. The search terms are illustrated in Table 1.

2.3. Inclusion criteria for study selection

The included articles must meet the following inclusion criteria:

(1) Case-control studies assessing the association between the LncRNAs expression level and NC.
(2) Patients diagnosed with NC in the case group and healthy people in the control group.
(3) Detailed LncRNAs expression level data provided.
(4) If serial studies from the same group of people were reported, including the latest study.
(5) The search was not limited to the language or date publication.

The criteria for excluding literature are summarized as follows:

(1) Non-human experiments were carried out.
(2) Repeatedly published literature.
(3) The lack of adequate information to calculate the statistical index standard mean difference.

2.4. Data collection and analysis

2.4.1. Selection of studies. All reviewers received evidence-based training and adhered to the process that was summarized based on the PRISMA flowchart (Fig. 1). The 2 authors independently screened the literature on the basis of the title, abstract and key words of the literature, and excluded the...
irrelevant literature. The rest of the literature would further confirm by the 2 authors after reading the full text. The excluded research and the reasons for the exclusion were recorded. The existing dispute was settled by the third author.

2.4.2. Data extraction and management. Two authors independently extracted the data from the eligible studies. Data entry was conducted using the EpiData software (version 3.0; The EpiData Association, Odense, Denmark). Disagreements were resolved by discussion or consensus with a third author.

If the LncRNAs expression level data was not directly reported, data was extracted from the statistical graph using Engauge Digitizer version 4.1 (Http://digitizer.sourceforge.net/). The following information was extracted: the first author, publishing year, country, ethnicity, specimen, detection method, sample size, etc.

2.5. Assessment of quality in included studies

The quality of all the included studies was evaluated by 2 authors independently based on the Newcastle-Ottawa scale that was used to evaluate the quality of observational studies. Disagreement were reported and resolved by a third author.

2.6. Measures of results

The data included in the study was continuous, standardized mean difference and 95% confidence interval analysis.

2.7. Management of missing data

If there is insufficient or missing data in the literature, we would contact the author via email to request the data. If the data is not available, we would only analyze the currently available data and discuss its potential impact.

2.8. Statistical analysis

Meta-analysis was performed using STATA 14.0 (STATA Corporation, College Station, TX). A random effects model
was used to identify the effect of each LncRNAs. The results were all presented as logORs, based on the numbers of dysregulation events in NP groups and control samples, with their 95%CI. Compared with control group, logOR values higher than 1 indicated LncRNAs up-regulation. The results were considered statistically significant for P values < .05. Prediction of LncRNAs targets was performed by Long Noncoding RNA Database v2.0, the LncRNA and Disease Database, Linc2GO Database and LNCipedia Database, and bioinformatic analysis including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis were performed by KOBAS 3.0. The −log10 (corrected P-Value) yields an enrichment score.

2.9. Additional analysis
2.9.1. Subgroup analysis. We conducted a subgroup analysis based on the sample type and detection method.

2.9.2. Sensitivity analysis. Sensitivity analysis was performed on the sample size.

2.9.3. Reporting bias. If the number of studies included in a certain outcome index is no less than 10, funnel chart is used to evaluate publication bias.[21,22]

2.10. Ethics and dissemination
It is not applicable for this systematic review and meta-analysis to require an ethical approval, because this study is not involved with individual patient data. Besides, this review would be disseminated in peer-review journals.

3. Discussion
NP is a kind of pain caused by injury or disease of the somatosensory system.[23–25] In the general population, the prevalence rate of NP is 6.9% Murray 10.0%, which seriously perplexes the life quality of patients and brings great burden to individuals, families and society.[26,27] Many factors, including injury or congenital disease,[28,29] can lead to neuropathic pain. Therefore, it is of great significance to explore the molecular targets of NP therapy. In recent years, scholars have explored a new way of targeted treatment of NP by regulating LncRNAs. Li et al discovered that IncRNA MRAK009713 plays an important regulatory role in the pain model of rats with chronic compressive injury.[30] MRAK009713 can promote pain by regulating the expression and function of P2X3 receptor. LncRNAs aggravates NP through promoting the release of pro-inflammatory factors or activating the phosphorylation of extracellular regulated protein kinases.[31] IncRNAs induces spontaneous abnormal electrical activity and hyperalgesia via regulating the expression of voltage-gated channels.[32] LncRNAs indirectly affects pain by regulating the expression of NP-related microRNA.[33] The above research implies the great prospect of the application of IncRNA in NP. However, the relationship between the expression of LncRNAs and NP remains unclear, which does not take the advantages of the further development of future researches. Therefore, there is an urgent need for a systematic review of the research on the relationship between the expression of LncRNAs and NP. This paper forms our system review scheme, which describes the implementation of the review in detail. The results of our review will be reported in strict accordance with PRISMA standards. By integrating the previous literature, this review objectively reveals the relationship between the expression of LncRNAs and NP. The results of this upcoming study will help us to understand the relationship between the expression of LncRNAs and NP, and will provide a reference for targeting new receptors to the treatment of NP.

The advantages of this study include following aspects: We include the latest literature. For the exploration of heterogeneity, we try to avoid post-group subgroup analysis. In order to improve the credibility of the results, we conduct sensitivity analysis. In addition, we will screen out different LncRNAs to point out the direction for future researches.

In summary, this study will provide up-to-date evidence support for the relationship between LncRNAs expression and NP, and provide a new strategy for targeted therapy of NP.

Author contributions
Conceptualization: Xianbao Yao.
Data curation: Yongzhi Fan and Na Li.
Formal analysis: Yongzhi Fan and Na Li.
Funding acquisition: Xianbao Yao.
Methodology: Yongzhi Fan and Na Li.
Project administration: Xianbao Yao.
Resources: Yongzhi Fan, Na Li.
Software: Na Li.
Supervision: Xianbao Yao, Na Li.
Validation: Xianbao Yao, Na Li.
Visualization and software: Yongzhi Fan and Na Li.
Visualization: Na Li.
Writing – original draft: Yongzhi Fan, Na Li and Xianbao Yao.
Writing – review & editing: Xianbao Yao, Yongzhi Fan, Na Li.

References
[1] Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895–926.
[2] Liu S, Zou L, Xie J, et al. LncRNA NONRATT021972 siRNA regulates neuropathic pain behaviors in type 2 diabetic rats through the P2X7 receptor in dorsal root ganglia. Mol Brain 2016;9:44.
[3] Wang S, Xu H, Zou L, et al. LncRNA uc.48 is involved in diabetic neuropathic pain mediated by the P2X3 receptor in the dorsal root ganglia. Poultry Sci 2016;12:139–48.
[4] LaCroix-Fralish ML, Austin JS, Zheng FY, et al. Patterns of pain: meta-analysis of microarray studies of pain. Pain 2011;152:1888–98.
[5] Oliveira RAA, Baptista AF, Sá KN, et al. Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 2020;78:741–52.
[6] Kim TW, Son SM, Lee JS. Neuropathic pain in ankylosing spondylitis: a meta-analysis. Zeitschrift fur Rheumatologie 2020;79:95–102.
[7] Bouchenaki H, Béguin M, Magy L, et al. Pharmacological management of neuropathic pain. Therapie 2019;74:63–43.
[8] Boyd A, Bleakley C, Hurley DA, et al. Herbal medicinal products or preparations for neuropathic pain. Cochrane Database Syst Rev 2019;4:CD010528.
[9] Finnerup NB, Haroutounian S, Baron R, et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain 2018;159:2339–46.
[10] Jiang BC, Sun WX, He LN, et al. Identification of IncRNA expression profile in the spinal cord of mice following spinal nerve ligation-induced neuropathic pain. Mol Pain 2015;11:143.
[11] Ruiz-Orea J, Meseguer X, Subarana JA, et al. Long non-coding RNAs as a source of new peptides. Elife 2014;3:e03523.
[12] Yu G, Yao W, Wang J, et al. LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PloS One 2012;7:e42377–42377.
[13] Kalpachidou T, Kummer KK, Kress M. Non-coding RNAs in neuropathic pain. Neuronal Signal 2020;4:NS20190099.
[14] Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013;152:1298–307.
[15] Li Z, Li X, Chen X, et al. Emerging roles of long non-coding RNAs in neuropathic pain. Cell Proliferation 2018;52:e12528.
[16] Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci 2016;73:2491–509.
[17] Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science (New York, NY) 2016;354:572–7.
[18] Liu S, Zou L, Xie J, et al. LncRNA NONRATT021972 siRNA regulates neuropathic pain behaviors in type 2 diabetic rats through the P2X7 receptor in dorsal root ganglia. Molecular Brain 2016;9:44.
[19] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed) 2015;350:g7647.
[20] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[21] Lewis SJ, Zammit S, Gunnell D, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
[22] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
[23] Meng C, Yang X, Liu Y, et al. Decreased expression of lncRNA Malat1 in rat spinal cord contributes to neuropathic pain by increasing neuron excitability after brachial plexus avulsion. J Pain Res 2019;12:1297–310.
[24] Tang S, Zhou J, Jing H, et al. Functional roles of lncRNAs and its potential mechanisms in neuropathic pain. Clin Epigenetics 2019;11:78.
[25] Iwashita H, Sakai A, Marruyama M, et al. Increased H19 Long Non-coding RNA Expression in Schwann Cells in Peripheral Neuropathic Pain. J Nippon Med Sch 2019;86:215–21.
[26] Liang Y, Yuan L, Li X, et al. Progress in research on janus kinase/signal transducer and activator of transcription3 and neuropathic pain. Chin J Exp Surg 2019;36:1505–7.
[27] Wu S, Bono J, Tao YX. Long noncoding RNA (lncRNA): a target in neuropathic pain. Expert Opin Ther Targets 2019;23:15–20.
[28] Yu W, Zhao GQ, Cao RJ, et al. LncRNA NONRATT021972 was associated with neuropathic pain scoring in patients with type 2 diabetes. Behav Neurol 2017;2017:1–7.
[29] Zhou J, Xiong Q, Chen H, et al. Identification of the spinal expression profile of non-coding mas involved in neuropathic pain following spared nerve injury by sequence analysis. Front Mol Neurosci 2017;10:91.
[30] Li G, Jiang H, Zheng C, et al. Long noncoding RNA MRAK009713 is a novel regulator of neuropathic pain in rats. Pain 2017;158:2042–52.
[31] Peng H, Zou L, Xie J, et al. LncRNA NONRATT021972 siRNA decreases diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia. Mol Neurobiol 2017;54:511–23.
[32] Zhao X, Tang Z, Zhang H, et al. A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. Nat Neurosci 2013;16:1024–31.
[33] Dou L, Lin H, Wang K, et al. Long non-coding RNA CCAT1 modulates neuropathic pain progression through sponging miR-155. Oncotarget 2017;8:89949–57.